Nav: Home

Researchers identify biomarkers of response to treatment in invasive breast cancer

December 08, 2016

CHAPEL HILL - Why do some breast cancers respond to treatment while others resist it? A study led by researchers at the University of North Carolina Lineberger Comprehensive Cancer Center may provide insight into this important question.

The researchers report at the San Antonio Breast Cancer Symposium that they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2-positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemotherapy.

"We're trying to find biomarkers for resistance to trastuzumab treatment and chemotherapy," said the study's first author Maki Tanioka, MD, PhD, a postdoctoral research associate at UNC Lineberger. "What's the cause of response? What's the cause of resistance? That's what we are trying to identify in this genomic study."

Tanioka and his colleagues analyzed multiple biologic features of cancer cells from 213 patients treated for HER2-positive breast cancer through a National Cancer Institute cooperative group clinical trial, CALGB 40601. The biologic features included multiple kinds of genetic information such as DNA mutations, DNA copy number and RNA gene expression data. The researchers found that certain gene signatures, and either having too many, or too few, of certain genes were predictive of whether patients responded to treatment, and that combining those two features was the most effective method of predicting response.

Examining features like mutations, amplifications or deletions of genes in tumor cells, the overall subtype of the tumor, as well as indicators of immune responses helped the researchers predict response. The researchers also determined that amplification of a specific chromosome, and a particular gene called MAPK14 on that chromosome, may be a predictor of sensitivity to treatment, while deletions of other genes predicted resistance.

The researchers say the next step is to identify another set of data to validate and broaden their findings.

"HER2-positive breast cancer is genomically heterogeneous," Tanioka said. "Therefore, we need a model that incorporates all these different features. We are actively seeking a set of patient data that we can use to validate the biomarkers we have identified so we can create a comprehensive predictive model of response to allow us to better tailor treatment."
In addition to Tanioka, other authors include: C. Fan, L.A. Carey, T. Hyslop, B.N. Pitcher, J. Parker, K.A. Hoadley, N.L. Henry, S. Tolaney, C. Dang, I.E. Krop, L. Harris, D.A. Berry, E. Mardis, C.M. Perou, E.P. Winer, and C.A. Hudis.

UNC Lineberger Comprehensive Cancer Center

Related Tumor Cells Articles:

When healthy cells stimulate the migration of tumor cells
Estrogens act as a driving force of both healthy and cancerous mammary cell growth by binding to receptors that include GPER, which is generally located in cell membranes.
Tumor cells get stiff before becoming invasive
A study published now on Nature Communications shows that breast cancer cells undergo a stiffening state prior to acquiring malignant features and becoming invasive.
Tumor-trained T cells go on patrol
In cancer, immune cells infiltrate tumors -- but it hasn't been known which immune cells exit the tumor or where they go next.
Tumor-dwelling immune cells thwart cancer immunotherapy
Researchers have caught tumor-associated immune cells called macrophages in the act of stealing checkpoint inhibitor antibodies away from their intended T cell targets, and blocking this thievery led to improved therapeutic responses in tumor-bearing mice.
Are tumor cells glutamine addicts?
Many tumors are thought to depend on glutamine, suggesting glutamine deprivation as therapeutic approach, but a new study shows that this effect might have been overestimated.
Tethered nanoparticles make tumor cells more vulnerable
MIT researchers have devised a way to make cancer cells more susceptible to certain types of cancer treatment, by coating the cells with nanoparticles before delivering drugs.
Researchers create viruses to selectively attack tumor cells
It is an innovative approach that takes advantage of the different expression profiles of certain proteins between tumor and healthy cells that make the virus to only infect the first ones.
Scientists use tumor-derived dendritic cells to slow tumor growth
In the human body, so-called dendritic cells are responsible for activating our immune system.
Tumor cells are dependent on fat to start metastasis
A study headed by Salvador Aznar Benitah, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona), and published today in Nature identifies metastasis-initiating cells through a specific marker, namely the protein CD36.
Once inside a tumor, our immune cells become traitors
New research has found a subset of our immune cells (called regulatory T cells) that are highly abundant in the tumor microenvironment and are particularly good at suppressing the anticancer immune response.

Related Tumor Cells Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".